Page last updated: 2024-08-24

triazoles and carfilzomib

triazoles has been researched along with carfilzomib in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (63.64)24.3611
2020's4 (36.36)2.80

Authors

AuthorsStudies
Sebestyén, Z; Szabó, B; Szepesi, K1
Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Kauffman, M; Kraftson, SJ; Maxwell, SP; Mayampurath, A; McCauley, D; Rosebeck, S; Shacham, S; Volchenboum, SL1
Hawkes, N1
Bauer, AA; Dai, Y; Dawson, JL; Gomez, J; Grant, S; Kashyap, T; Landesman, Y; Meads, M; Shain, KH; Sullivan, DM; Turner, JG1
Musi, E; Nair, JS; Schwartz, GK1
Bajpai, R; Hall, WD; Lonial, S; Qian, G; Shanmugam, M; Sun, SY; Yao, W; Zhang, S1
Chari, A; Cole, CE; Hycner, T; Jakubowiak, AJ; Jasielec, JK; Karrison, T; McIver, A; Mikhael, J; Nam, J; Rosebeck, S; Rosenbaum, CA; Severson, E; Stephens, LA; Tinari, K; Turowski, A; Zimmerman, TM; Zonder, JA1
Potluri, A; Radhakrishnan, SK; Vangala, JR1
Dakle, P; Jeitany, M; Jiang, YY; Kanojia, D; Kappei, D; Koeffler, HP; Landesman, Y; Madan, V; Mukundan, V; Pathak, E; Prabhu, A; Tam, WL1
Forsberg, P; Mark, TM; Sherbenou, D; Stalker, M1
Ammu, S; Bahlis, NJ; Baljevic, M; Ben-Shahar, O; Bensinger, WI; Bentur, OS; Biran, N; Callander, NS; Chen, CI; DeCastro, A; Gasparetto, C; Kauffman, M; Kotb, R; LeBlanc, R; Lentzsch, S; Lipe, B; Madan, S; Rossi, AC; Schiller, GJ; Sebag, M; Shacham, S; Shah, J; Sutherland, HJ; Tuchman, SA; Van Domelen, D; Venner, CP; White, D; Zhang, C; Zhou, T1

Reviews

1 review(s) available for triazoles and carfilzomib

ArticleYear
[Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:2

    Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antiemetics; Antifungal Agents; Antipsychotic Agents; Aripiprazole; beta-Cyclodextrins; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Humans; Hungary; Multiple Myeloma; Oligopeptides; Piperazines; Pyrimidines; Quinolones; Quinuclidines; Solubility; Thiazoles; Triazoles; Voriconazole

2013

Trials

2 trial(s) available for triazoles and carfilzomib

ArticleYear
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    British journal of haematology, 2019, Volume: 186, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Prognosis; Recurrence; Retreatment; Treatment Outcome; Triazoles

2019
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
    British journal of cancer, 2022, Volume: 126, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Analysis; Translocation, Genetic; Treatment Outcome; Triazoles

2022

Other Studies

8 other study(ies) available for triazoles and carfilzomib

ArticleYear
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Caspase 10; Caspase 8; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Enzyme Activation; Humans; Hydrazines; Intracellular Space; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Triazoles; Xenograft Model Antitumor Assays

2016
European drug agency launches website giving open access to trial data.
    BMJ (Clinical research ed.), 2016, Oct-21, Volume: 355

    Topics: Access to Information; Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Europe; Gout; Gout Suppressants; Humans; Internet; Multiple Myeloma; Oligopeptides; Thioglycolates; Triazoles

2016
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Oligopeptides; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Time Factors; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays

2016
Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-01, Volume: 23, Issue:15

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Survival; Exportin 1 Protein; Humans; Hydrazines; I-kappa B Proteins; Inhibitor of Apoptosis Proteins; Karyopherins; Mice; NF-kappa B; Oligopeptides; Receptors, Cytoplasmic and Nuclear; Sarcoma; Survivin; Transcription Factor RelA; Triazoles; Xenograft Model Antitumor Assays

2017
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
    Cancer letters, 2018, 10-28, Volume: 435

    Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; HCT116 Cells; Humans; Mice, Nude; Neoplasms; Oligopeptides; Proteasome Inhibitors; Proteins; RNA Interference; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays

2018
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response.
    Biomolecules, 2020, 03-26, Volume: 10, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzodiazepines; Cell Death; Cell Line, Tumor; Drug Synergism; Heterocyclic Compounds, 4 or More Rings; Humans; NF-E2-Related Factor 1; Oligopeptides; Proteasome Inhibitors; Triazoles; Unfolded Protein Response

2020
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
    Cellular and molecular life sciences : CMLS, 2021, Volume: 78, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Fatty Acid Desaturases; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Liposarcoma; Oligopeptides; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Cytoplasmic and Nuclear; Triazoles

2021
Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Homologous; Treatment Outcome; Triazoles

2021